Riemser Pharma
| RIEMSER Pharma GmbH
|
|
|---|---|
 |
|
| legal form | GmbH |
| founding | 1992 |
| Seat | Greifswald , Mecklenburg-Western Pomerania |
| management |
|
| Number of employees | > 200 (2017) |
| sales | 110 million euros (2013) |
| Branch | drug |
| Website | www.riemser.com |
The Riemser Pharma GmbH is a pharmaceutical company that provides human use produced and marketed. The headquarters are on the island of Riems in Mecklenburg-Western Pomerania, part of Greifswald .
The product range mainly includes prescription drugs for supportive and palliative treatment in the oncological field , tuberculosis drugs , as well as preparations for the treatment of infectious and skin diseases.
history
The origins of the group go back to the Friedrich-Loeffler-Institut founded in 1910 on the island of Riems .
In 1990 the production of the Friedrich Loeffler Institute was outsourced. From then on it traded under the name of Riemser Tierarzneimittel . In 1992 Riemser was privatized and sold to Norbert Braun and his wife Dagmar Braun . In 1996 a distribution center was established in Riemserort, in 1997 the company was renamed Riemser Arzneimittel and several drug approvals were obtained from Akzo Nobel , GlaxoSmithKline , Johnson & Johnson , Knoll , Solvay and Wyeth . In addition to the veterinary sector, the focus was on dietary supplements and pharmaceutical products.
In 2000 the Leipziger Arzneimittelwerk was bought. Since 2001 Riemser was a stock corporation (Riemser Arzneimittel AG). In 2002, Riemser Pharma took over Dessau and Bioglan Pharma . This was followed by the Roesch AG (2003), Fatol drug (2006), Bionic Solution Management (2006), Rentschler Pharma (2008) (renamed Riemser Specialty Production) and 2008 dental technology field of Curasan AG .
Norbert Braun, CEO of Riemser, handed over management to Michael Mehler in 2009.
In 2010 the anti-infective portfolio from Grünenthal was purchased . In 2011 the veterinary business of Riemser was sold to Ecuphar from Belgium. In the same year Beatrice von Buchwaldt was appointed as the company's new CFO. In addition, a license agreement was signed with Helsinn Healthcare regarding the marketing rights in Germany for a fixed dose combination containing netupitant and palonosetron .
In 2012, Riemser bought the international rights to a bisphosphonate for cancer therapy from Hoffmann-La Roche and took a stake in Anwerina.
In 2013 Curasan explicitly took over a large part of the "Oral Regenerative Medicine" division from Riemser, and the Prange Group took over the Leipziger Arzneimittelwerk in the same year.
AXA Private Equity has been a partner in the group since 2012. AXA Private Equity has been operating as an independent investment company under the name Ardian since September 30, 2013. Since December 1st, 2012, Riemser is again a limited liability company under the name of Riemser Pharma GmbH. Riemser operates internationally.
Web links
Individual evidence
- ↑ a b c fact sheet. (PDF; 329 kB) Riemser Pharma, September 2017, accessed on November 23, 2017 .
- ↑ Riemser Pharma GmbH remains successful. In: ostsee-zeitung.de. January 29, 2013, accessed November 23, 2017 .
- ↑ bionity.com: Curasan acquires dental business from Riemser Pharma
- ↑ LAW website
Coordinates: 54 ° 10 ′ 49.2 " N , 13 ° 20 ′ 35.8" E